Global Immune Thrombocytopenia Drugs Market 2019-2023

免疫性血小板減少症薬の世界市場:TPO-RA、コルチコステロイド、IVIG、その他の薬

◆タイトル:Global Immune Thrombocytopenia Drugs Market 2019-2023
◆商品コード:IRTNTR31389
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年5月29日
◆ページ数:136
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、米州、アジア太平洋、EMEA(ヨーロッパ・中東・アフリカ)
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、免疫性血小板減少症薬の世界市場について調べ、免疫性血小板減少症薬の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、免疫性血小板減少症薬の市場規模をセグメンテーション別(製品別(TPO-RA、コルチコステロイド、IVIG、その他の薬))と地域別(グローバル、米州、アジア太平洋、EMEA(ヨーロッパ・中東・アフリカ))に分けて算出しました。
・サマリー
・レポートの範囲
・免疫性血小板減少症薬の市場状況
・免疫性血小板減少症薬の市場規模
・免疫性血小板減少症薬の市場予測
・免疫性血小板減少症薬の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(TPO-RA、コルチコステロイド、IVIG、その他の薬)
・免疫性血小板減少症薬の顧客状況
・主要地域別市場規模:グローバル、米州、アジア太平洋、EMEA(ヨーロッパ・中東・アフリカ)
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...

About this market

Immune thrombocytopenia is common among young women, and its risk is higher in people with diseases such as rheumatoid arthritis, HIV, hepatitis, lupus, and antiphospholipid syndrome. The prevalence of these diseases is high across the world. For instance, in 2016, over a million people in the US were diagnosed with HIV infection, and nearly 1% of the adults in the US had Hepatitis C. The growing incidences of such risk factors will increase the prevalence of immune thrombocytopenia. This will increase the demand for treatment options, thereby driving the growth of the global immune thrombocytopenia market size at a CAGR of nearly 5% during the forecast period.

Market Overview

Expected approvals for late-stage pipeline molecules

The market is witnessing accelerated growth in the number of molecules in the pipeline for the treatment of immune thrombocytopenia. At present, there are over 5 therapeutics to treat immune thrombocytopenia. These drugs are in the late stages of development and are slated to receive marketing approvals during the forecast period.

Availability of substitutes

The side effects associated with the available drugs for the treatment of immune thrombocytopenia are forcing healthcare practitioners to adopt alternative treatment options such as platelet transfusion and surgery. These treatment options have higher efficacies when compared to the available drugs. This is expected to pose a challenge to the growth of the global immune thrombocytopenia market size.

For the detailed list of factors that will drive and challenge the growth of the immune thrombocytopenia market size during 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented with several players occupying the market share. Companies such as Amgen Inc. and CSL Ltd. Have intensified the competition. Factors such as the high prevalence of associated risk factors for immune thrombocytopenia and the expected approvals of late-stage pipeline molecules will provide significant growth opportunities for immune thrombocytopenia drug manufacturers. Amgen Inc., CSL Ltd., Horizon Therapeutics Plc, Merck & Co. Inc., Novartis AG, and Rigel Pharmaceuticals Inc. are some of the major companies covered in this report.

【資料の目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

TPO-RAs – Market size and forecast 2018-2023

Corticosteroids – Market size and forecast 2018-2023

IVIGs – Market size and forecast 2018-2023

Other drugs – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Special regulatory designations

Increasing number of awareness programs

Development of biosimilars

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Amgen Inc.

CSL Ltd.

Horizon Therapeutics Plc

Merck & Co., Inc.

Novartis AG

Rigel Pharmaceuticals Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global hematology drugs market

Exhibit 02: Segments of global hematology drugs market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Product – Market share 2018-2023 (%)

Exhibit 18: Comparison by product

Exhibit 19: TPO-RAs – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Approved TPO-RAs

Exhibit 21: Pipeline of TPO-RAs

Exhibit 22: TPO-RAs – Year-over-year growth 2019-2023 (%)

Exhibit 23: Corticosteroids – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: Some of the generic sponsors for corticosteroids

Exhibit 25: Corticosteroids – Year-over-year growth 2019-2023 (%)

Exhibit 26: IVIGs – Market size and forecast 2018-2023 ($ millions)

Exhibit 27: Some of the available IVIGs

Exhibit 28: Side effects of IVIGs

Exhibit 29: Approximate Costs of IVIGs

Exhibit 30: IVIGs – Year-over-year growth 2019-2023 (%)

Exhibit 31: Other drugs – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Off-label drugs for immune thrombocytopenia

Exhibit 33: Other drugs – Year-over-year growth 2019-2023 (%)

Exhibit 34: Market opportunity by product

Exhibit 35: Customer landscape

Exhibit 36: Market share by geography 2018-2023 (%)

Exhibit 37: Geographic comparison

Exhibit 38: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: North America – Year-over-year growth 2019-2023 (%)

Exhibit 40: Top 3 countries in North America

Exhibit 41: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 42: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 43: Top 3 countries in Europe

Exhibit 44: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 45: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 46: Top 3 countries in Asia

Exhibit 47: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 48: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 49: Top 3 countries in ROW

Exhibit 50: Key leading countries

Exhibit 51: Market opportunity

Exhibit 52: Prevalence of associated risk factors for immune thrombocytopenia

Exhibit 53: Drug development pipeline for immune thrombocytopenia

Exhibit 54: Side effects associated with available drugs

Exhibit 55: Alternative therapies for immune thrombocytopenia

Exhibit 56: Impact of drivers and challenges

Exhibit 57: Drug designations

Exhibit 58: Vendor landscape

Exhibit 59: Landscape disruption

Exhibit 60: Vendors covered

Exhibit 61: Vendor classification

Exhibit 62: Market positioning of vendors

Exhibit 63: Amgen Inc. – Vendor overview

Exhibit 64: Amgen Inc. – Business segments

Exhibit 65: Amgen Inc. – Organizational developments

Exhibit 66: Amgen Inc. – Geographic focus

Exhibit 67: Amgen Inc. – Key offerings

Exhibit 68: Amgen Inc. – Key customers

Exhibit 69: CSL Ltd. – Vendor overview

Exhibit 70: CSL Ltd. – Business segments

Exhibit 71: CSL Ltd. – Organizational developments

Exhibit 72: CSL Ltd. – Geographic focus

Exhibit 73: CSL Ltd. – Segment focus

Exhibit 74: CSL Ltd. – Key offerings

Exhibit 75: CSL Ltd. – Key customers

Exhibit 76: Horizon Therapeutics Plc – Vendor overview

Exhibit 77: Horizon Therapeutics Plc – Business segments

Exhibit 78: Horizon Therapeutics Plc – Organizational developments

Exhibit 79: Horizon Therapeutics Plc – Geographic focus

Exhibit 80: Horizon Therapeutics Plc – Segment focus

Exhibit 81: Horizon Therapeutics Plc – Key offerings

Exhibit 82: Horizon Therapeutics Plc – Key customers

Exhibit 83: Merck & Co. Inc. – Vendor overview

Exhibit 84: Merck & Co. Inc. – Business segments

Exhibit 85: Merck & Co. Inc. – Organizational developments

Exhibit 86: Merck & Co. Inc. – Geographic focus

Exhibit 87: Merck & Co. Inc. – Segment focus

Exhibit 88: Merck & Co. Inc. – Key offerings

Exhibit 89: Merck & Co. Inc. – Key customers

Exhibit 90: Novartis AG – Vendor overview

Exhibit 91: Novartis AG – Business segments

Exhibit 92: Novartis AG – Organizational developments

Exhibit 93: Novartis AG – Geographic focus

Exhibit 94: Novartis AG – Segment focus

Exhibit 95: Novartis AG – Key offerings

Exhibit 96: Novartis AG – Key customers

Exhibit 97: Rigel Pharmaceuticals Inc. – Vendor overview

Exhibit 98: Rigel Pharmaceuticals Inc. – Business segments

Exhibit 99: Rigel Pharmaceuticals Inc. – Organizational developments

Exhibit 100: Rigel Pharmaceuticals Inc. – Key offerings

Exhibit 101: Rigel Pharmaceuticals Inc. – Key customers

Exhibit 102: Validation techniques employed for market sizing

Exhibit 103: Definition of market positioning of vendors



【掲載企業】

Amgen Inc.、CSL Ltd.、Horizon Therapeutics Plc、Merck & Co., Inc.、Novartis AG、Rigel Pharmaceuticals Inc.

★調査レポート[免疫性血小板減少症薬の世界市場:TPO-RA、コルチコステロイド、IVIG、その他の薬] (Global Immune Thrombocytopenia Drugs Market 2019-2023 / IRTNTR31389)販売に関する免責事項
[免疫性血小板減少症薬の世界市場:TPO-RA、コルチコステロイド、IVIG、その他の薬] (Global Immune Thrombocytopenia Drugs Market 2019-2023 / IRTNTR31389)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆